Ambitious Breast Cancer Clinical Trial Program Ramps Up at USC Norris Comprehensive Cancer Center
Breast cancer oncologist Daphne Stewart, MD, explains why Keck Medicine’s USC Norris Comprehensive Cancer Center is working to expand patient access to breast cancer clinical trials
Clinical Scorecard: Ambitious Breast Cancer Clinical Trial Program Ramps Up at USC Norris Comprehensive Cancer Center
At a Glance
Category Detail
Condition Breast Cancer Key Mechanisms Investigation of novel therapies, including vaccines and T cell therapy, and personalized treatment based on cancer gene profiling. Target Population Breast cancer patients, including those with early-stage and advanced breast cancer. Care Setting Keck Medicine of USC, USC Norris Comprehensive Cancer Center
Key Highlights
More than 25 clinical trials for breast cancer patients currently offered. Focus on increasing clinical trial participation post-COVID-19 pandemic. Investigation of curative therapy prior to surgery based on cancer gene profiling. Exploration of less invasive treatment options with fewer side effects. Multidisciplinary teams review patient cases weekly for trial suitability. Guideline-Based Recommendations
Diagnosis
Utilize cancer gene profiling to tailor treatment approaches. Management
Consider clinical trials for patients who have exhausted standard-of-care options. Monitoring & Follow-up
Regular review of patient cases by multidisciplinary teams to assess trial eligibility. Risks
Potential side effects from standard treatments such as chemotherapy and radiation. Patient & Prescribing Data
Breast cancer patients at Keck Medicine, including premenopausal women.
Exploration of endocrine therapy as a less toxic alternative to chemotherapy.
Clinical Best Practices
Maintain a diverse portfolio of clinical trials to match patients with appropriate options. Encourage patient participation in clinical trials to advance treatment options. References
